A recent study indicates that individuals who discontinue popular GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who stop conventional lifestyle programs.
Published data in a major medical journal demonstrates that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing these treatments need to be aware of the risk of quick rebound weight gain when the medication concludes," warns lead investigator Dr. Susan Jebb.
Such speed of regain suggests a return to original mass in about a year and a half.
Weighing Approaches
The research, which reviewed dozens of studies involving thousands of patients, compared the effects of the injectable medications with older methods.
Researchers point out that people who lose weight through lifestyle changes alone typically see a slower weight regain—perhaps 100 grams monthly—post-intervention.
The Reason for the Rapid Rebound
Doctors propose the mechanism of the drugs is key to understanding the heightened weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of the hormone levels far above than normal could lead to the system to produce less of its endogenous GLP-1, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to hunger is uncontrolled, making binge eating far more likely."
An Ongoing Disease?
The NHS suggest the jabs for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts contend that, due to the likelihood of weight regain, the therapy is often life-long.
This opinion is supported by pharmaceutical companies, who note that the findings "highlight the persistent character of obesity," akin to managing conditions like hypertension.
Patient Experiences
Individuals who have stopped the jabs describe a sudden resurgence of hunger.
"It felt as if something flipping and you become ravenous," recalled one woman.
The struggle is compounded if individuals have not established sustainable lifestyle or habit modifications during therapy.
Widespread Adoption
Survey data indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on ongoing lifestyle management.
